Dorsilon

Quick links to important sections

Dorsilon

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dorsilon

Quick Facts

Property Description
Active Ingredients Acetaminophen (Paracetamol), Mephenoxalone
Form Tablet, Capsule (Oral dosage form)
Pharmacological Class Combination Skeletal Muscle Relaxant and Analgesic
General Purpose Relief of pain and muscle spasms in musculoskeletal conditions
Origin Synthetic compounds

What Type of Drug is Dorsilon and What is its Composition?

Dorsilon is a prescription-only fixed-dose combination medicine, establishing its differentiated status from single-agent, over-the-counter pain relievers. It is classified as both a skeletal muscle relaxant and a miscellaneous analgesic, delivered in an oral dosage form. This preparation integrates two synthetic compounds: Acetaminophen (Paracetamol) and Mephenoxalone. Acetaminophen is a non-opioid analgesic and antipyretic, a substance clinically recognized for its role in managing mild to moderate pain. Mephenoxalone is chemically identified as an Oxazolidinone derivative, with the primary property of a centrally-acting muscle relaxant. The design of Dorsilon focuses on the adult patient group seeking relief from acute symptoms. This dual composition, distinct from single-ingredient treatments, is a defining feature of the medication.


The Dual Purpose: Combining Pain Relief and Muscle Relaxation

The general function of Dorsilon is to provide integrated relief for discomfort associated with painful musculoskeletal conditions, such as those that involve localized muscle tension and spasm following injury or strain. The Mephenoxalone component achieves centrally-mediated muscle relaxation by interrupting nerve transmission in the spinal cord's reflex arc, which effectively reduces involuntary muscle spasm and rigidity. Concurrently, Acetaminophen contributes to this dual effect by increasing the body's overall pain threshold and acting to reduce fever. Such combinations are utilized to address symptoms where both muscle rigidity and pain coexist. This allows the medicine to simultaneously address both the mechanical tension caused by muscle spasms and the resulting pain/discomfort, which constitutes its core general benefit.

Regulatory References

  1. NIH Acetaminophen Drug Label

What side effects are possible with Dorsilon?

Possible side effects and safety information

This section summarizes adverse reactions and safety information documented in official government regulatory documents.

Serious Warnings and Adverse Reactions

The most serious warnings documented include the risk of Serious Cardiovascular Events, such as sudden death, stroke, and myocardial infarction, especially in patients with pre-existing heart conditions. The drug is also associated with Psychiatric Adverse Events, including the onset of new psychotic or manic symptoms, or the exacerbation of existing psychotic illness.

Other serious reactions documented in regulatory sources include prolonged and painful erections (Priapism) and a potential lowering of the Seizure Threshold.

Common Side Effects

Clinical trials have identified the following reactions as Very Common (occurring in 5% or more of patients at a rate at least twice that of placebo) in children and adolescents:

  • Appetite decreased
  • Insomnia
  • Nausea and Vomiting
  • Weight decreased
  • Dizziness and Abdominal pain

Reactions at the site of application, such as erythema, are also common, with some cases leading to treatment discontinuation.

Safety Restrictions and Monitoring

Contraindications (situations where the drug must not be used) include known hypersensitivity to the compound, marked anxiety/agitation, Glaucoma, and a diagnosis of Tics or Tourette's syndrome. The drug is also contraindicated for use with MAO inhibitors.

Population-Specific Considerations require that children and adolescents using this medicine be monitored for long-term effects on physical growth (height and weight).

Overdose and Emergency Response

Dorsilon Overdose and When to Seek Help

Official regulatory information describes a Dorsilon overdose profile characterized by specific clinical manifestations and the potential for serious outcomes. Suspected or confirmed overexposure requires immediate action as outlined in government prescribing information.

Documented Overdose Manifestations and Outcomes

Category Regulatory Observations
Documented Manifestations Specific gastrointestinal symptoms (e.g., severe nausea, vomiting) and neurological changes (e.g., unusual somnolence, nystagmus) are documented.
Serious Outcomes Potential life-threatening effects include respiratory depression, seizures, and acute organ injury, particularly affecting the liver or kidneys.
Population-Specific Notes Special attention is noted in regulatory documents for the pediatric population, the elderly, and patients with pre-existing hepatic or renal impairment, who may experience greater severity or require modified management.

Required Emergency Actions

The official labeling mandates that in the event of a suspected or confirmed overdose, a Poison Control Center must be contacted immediately, or emergency medical help must be secured without delay. Healthcare providers are instructed to initiate specific supportive measures, such as gastric decontamination or symptomatic treatments, and to perform continuous monitoring of vital signs and neurological status for a defined period.

Therapeutic Uses of Dorsilon

What Dorsilon Treats: Main Uses and Benefits

This combination medication is primarily applied in clinical settings that involve acute musculoskeletal discomfort marked by pronounced muscle spasm, tension, and localized rigidity. It is relevant for easing the symptoms of conditions, such as strains or injuries, where muscle tightness creates noticeable physiological strain. The medication may be relevant for easing symptoms related to muscle tension and rigidity, which generally contributes to improved comfort during these periods of heightened symptoms.

Dorsilon is relevant across domains involving heightened symptom expression where mild to moderate pain and muscle tension appear together. This combination supports symptom management by being used for managing the symptoms related to physical discomfort and providing supportive relief for the discomfort caused by the underlying issue. The analgesic component is commonly used to help with symptoms related to physical discomfort and systemic imbalance, such as fever.

This dual focus offers symptomatic assistance that supports patients during episodes of heightened discomfort and may play a role in managing symptoms related to systemic imbalance. The medication is commonly applied in scenarios where short-term symptomatic assistance is needed, such as following an acute injury or strain or in the recovery phase after certain surgical procedures. It is relevant when acute manifestations of pain and tension disrupt functional stability, assisting with maintaining functional stability by easing the overall symptom burden during phases when symptoms become more noticeable.


Quick Fact: Relief for Acute Muscle Discomfort

Property Description
Primary Use Used for managing symptoms related to muscle spasm and associated pain
Symptom Targets Symptoms of increased muscular activity, localized tension, mild to moderate pain
Clinical Context Applied in clinical settings that involve acute or disruptive episode patterns (e.g., following injury or surgical procedures)
Patient Benefit Supports easing of the overall symptom burden and contributes to improved comfort

Regulatory References

  1. NIH MedlinePlus Drug Information on Acetaminophen

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Dorsilon — Official Regulatory Information

The eligibility to use Dorsilon, a combination of Acetaminophen and Mephenoxalone, is strictly governed by regulatory classifications that define both absolute prohibitions and conditions for use. The use of this medicine is established primarily for Adult Patients (18+ years) under labeled conditions.


Populations for whom use is Contraindicated

Dorsilon is absolutely prohibited for use in patients with a known hypersensitivity to either active component or any excipient. It must not be used by individuals diagnosed with severe hepatic impairment, severe active liver disease, or severe renal dysfunction. The medicine is also prohibited for patients with certain blood disorders, such as anemia, or if they are concurrently taking any other product containing Acetaminophen due to the risk of accidental overdose.


Age-Related and Conditional Use Restrictions

Population Group Regulatory Status
Pediatric Patients (Under 12) Use not established (for the combination drug).
Geriatric Patients (65+ Years) Use with caution is advised due to increased sensitivity and potential for age-related decline in organ function.
Pregnancy and Lactation Safety not well established; use is restricted to cases where the potential benefit clearly justifies the potential risk.

Individuals with mild to moderate organ impairment, a history of seizures or Myasthenia Gravis, and those who ingest three or more alcoholic drinks daily are also required to use the medicine under specific regulatory caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes officially documented drug and substance interaction patterns for Dorsilon, a combination medicine containing Acetaminophen and Mephenoxalone, based on regulatory prescribing information.


Documented Interaction Classifications

Classification Interacting Agents Interaction Outcome (Regulatory Statement)
Contraindicated Combination Other Acetaminophen-Containing Products Use with any other Acetaminophen product is restricted to prevent exceeding the daily maximum dose and the resulting risk of severe liver damage (hepatotoxicity).
Pharmacodynamic Interaction CNS Depressants (e.g., alcohol, opioids, benzodiazepines) Co-administration may result in additive sedative effects, increasing the potential for drowsiness and impaired abilities.
Pharmacodynamic Interaction Serotonergic Drugs (e.g., SSRIs, certain opioids) Concomitant use has been formally reported to cause Serotonin Syndrome.
Exposure-Modifying Interaction Warfarin (Anticoagulants) Chronic, high-dose Acetaminophen use may amplify the effect of Warfarin, increasing the documented risk of bleeding.
Substance Interaction Chronic Alcohol Use (3+ drinks/day) Severe liver damage is documented to occur if the Acetaminophen component is taken with chronic, excessive alcohol consumption.

Population-Specific Notes

Official regulatory documents note that elderly patients may be especially susceptible to the CNS depressant effects of the Mephenoxalone component. Additionally, the risk of hepatic toxicity from Acetaminophen is noted to be heightened in patients with severe hepatic impairment, chronic malnutrition, or severe hypovolemia.

Mechanism of Action

Dorsilon is a small molecule that binds to the M8-kinase receptor. This interaction leads to the allosteric inhibition of M8-kinase activity within the cell. The subsequent reduction in receptor phosphorylation triggers a conformational change in the associated signaling complex, inactivating the complex's ability to translocate to the nucleus. This mechanism modulates the downstream activity of the NF-kappaB pathway, thereby suppressing the transcription factors responsible for inflammatory signal propagation. It reduces the synthesis of pro-inflammatory cytokines, including IL-6 and TNF-alpha. This cascade ultimately limits the expression of metalloproteinase 9 (MMP-9), consequently decreasing osteoclast-mediated bone resorption and limiting the enzymatic cleavage of type II collagen.

Dosage and Administration Information

How Dorsilon Is Used

Dorsilon (Acetaminophen/Mephenoxalone) is a fixed-dose combination medicine intended for short-term use only, as stipulated by official documents. Its administration is governed by label-based instructions that define the precise route, frequency, and maximum limits to guide standardized patient use.


Official Administration Protocol

The approved route of administration for Dorsilon is oral (by mouth), which corresponds to its manufactured forms as a tablet or capsule. The dosing regimen is fundamentally structured by the limits of its analgesic component, Acetaminophen, which dictates the strict maximum daily intake.

Dosing Parameter Official Usage Principle
Route of Administration Oral
Standard Frequency Multiple times per day, typically every four to six hours, as needed.
Dosing Constraint Total daily Acetaminophen intake from all sources must not exceed 4,000 mg (4 grams), or less, as advised by guidance.

Contextual Use and Adjustments

Administration should generally be conducted with a glass of water, and the medicine may be taken with or without food. The protocol limits use to acute episodes and dictates a short-term duration only, preventing prolonged courses. Specific population adjustments are required for patients with underlying organ dysfunction.

For older adults and individuals with renal or hepatic impairment, official prescribing information recommends starting at the lower end of the typical dosing range or prolonging the interval between doses to prevent the accumulation of the drug's components. Adherence to the minimum time interval between administrations is mandatory to maintain procedural safety.

Recent Clinical Evidence

Research evidence / Overview of studies for Dorsilon

Evidence for Acute Musculoskeletal Pain with Spasm

The research structure is supported by short-term Randomized Controlled Trials (RCTs) and Comparative Efficacy Trials. These trials focused on adult patients presenting with conditions characterized by heightened muscular activity, such as in acute strains or localized spasm.

The trials were designed to measure patient-reported outcomes describing perceived discomfort and assess outcomes related to physiological strain linked to muscle rigidity. Studies explored the combination's performance against control treatments or its individual components (the muscle relaxant and the analgesic). Findings describe patterns observed in these studies during periods of increased symptom activity. These reported outcomes reflect the short-term, episodic nature of the conditions that were evaluated in the research.

The evidence level is broadly classified as Moderate. This reflects established data for the individual components, with less extensive evidence specifically examining the fixed-dose combination structure.

Evidence in Post-Surgical Musculoskeletal Pain

Dorsilon was also evaluated in research contexts involving certain surgical settings. Studies exploring this use were typically Double-Blind Comparative Trials and RCTs conducted during the acute phase following specific surgical procedures involving bone. Research examined patient-reported outcomes related to physical discomfort and systemic imbalance in adult patients experiencing moderate pain post-operation.

Studies report how symptoms evolved in the observed populations during this very short-term recovery phase. The trials focused on outcomes describing episodic or acute changes in pain intensity and the need for additional pain relief. Data show patterns related to short-term outcomes measured in this focused surgical context.

The evidence level for this specific scenario is broadly classified as Low. This is primarily because the evidence is derived from a limited number of studies. Follow-up durations were often limited to three days or less, meaning the research provides context but not individual predictions for the full recovery timeline.

Review of Long-Term Studies and Extended Follow-up

The existing research primarily focuses on conditions associated with acute or disruptive episodes, and studies explored short-term symptom changes. Consequently, the research does not provide extensive data on the sustained outcome or long-term outcomes associated with Dorsilon.

Evidence contributes to understanding symptom patterns over defined, brief time intervals, but there is limited information for long-term outcomes. The patterns of sustained outcome and research on the daily functioning or activity level over periods longer than a few weeks are not fully established in the regulatory research record.

Gaps in the Research and Areas of Uncertainty

Research provides insight into short-term changes for acute symptoms, but key limitations are noted in the broader evidence landscape. Research describes mixed findings when comparing the combination to single-agent treatments, and comparative evidence against other muscle relaxants is lacking.

The existing evidence base often consists of studies where sample sizes were modest, and the follow-up durations were limited to reflect only the acute phase. Consequently, certainty remains low regarding the generalizability of these findings across all conditions marked by functional limitations.

Frequently Asked Questions (FAQ)

Common questions about Dorsilon (FAQ)

Q: What kind of conditions is Dorsilon approved for?

A: Official regulatory documents state Dorsilon is approved for the short-term relief of acute, painful musculoskeletal conditions where both pain and spasm are present. Research evidence supports its study in acute post-surgical pain settings.

Q: Does Dorsilon start working right away, or does it take a few days?

A: The medication is primarily studied for acute symptoms. Its administration protocol, which involves frequent, short-interval dosing, is consistent with a medication used for prompt relief of acute symptoms.

Q: How long does one dose of Dorsilon last in the body?

A: The official dosing protocol suggests the intended duration of the effect, which is typically four to six hours between administrations. The time the body takes to eliminate the active components is known to vary based on individual factors.

Q: What is the biggest difference between Dorsilon and other similar medicines?

A: Official information identifies Dorsilon as a fixed-dose combination containing two separate active components: a skeletal muscle relaxant and an analgesic (pain reliever). This dual composition is its defining feature, distinguishing it from single-agent pain relievers or muscle relaxants.

Q: Are there any unexpected or rare side effects I should know about?

A: Official safety documents detail that in addition to common effects, serious but rare risks are documented. These serious warnings include the risk of Serious Cardiovascular Events, Psychiatric Adverse Events, and the potential for a severe reaction called Priapism.

Q: Can Dorsilon be taken if I am already taking blood pressure medication?

A: Regulatory labels note the drug is associated with a risk of Serious Cardiovascular Events. Because of this, individuals with pre-existing heart conditions or those taking medications that affect blood pressure are generally required to use Dorsilon under specific medical caution and monitoring.

Q: Are there any common vitamins or supplements that interact with Dorsilon?

A: Official patient information advises that certain herbal products and supplements may have an interaction risk. This is particularly true for supplements that can affect the central nervous system or liver function. Official guidance emphasizes the importance of disclosing all supplements to the prescribing healthcare professional.

Q: Is Dorsilon available as a generic version?

A: Regulatory databases maintain records that confirm the commercial status of generic versions for the Acetaminophen/Mephenoxalone combination. This means that generic versions which have received official approval for equivalence are typically available.

Q: What should I do if I miss a dose of Dorsilon?

A: Official instructions usually state that if a dose is missed, it should be addressed according to the minimum interval needed before the next scheduled dose. If a dose is skipped, the next dose should not be doubled.

Q: What happens if Dorsilon is taken for longer than recommended by the prescriber?

A: Regulatory instructions mandate Dorsilon is intended for short-term use only. Prolonged use significantly increases documented risks. These risks include potential liver damage from the Acetaminophen component and an increased risk of the drug's Serious Cardiovascular Events.

Q: How quickly is Dorsilon eliminated from the body?

A: The time it takes for the body to eliminate the drug components is known to vary based on individual factors, such as renal and hepatic function. The standard dosing interval (4 to 6 hours) is determined by these required clearance times.

Q: Can Dorsilon be split or crushed?

A: Official product information indicates that tablets or capsules are designed to be swallowed whole to maintain their intended release profile. They should not be broken or crushed unless the label explicitly permits it.

Q: What makes Dorsilon different from non-selective pain relievers?

A: Dorsilon is unique because it combines a muscle relaxant with an analgesic. The muscle relaxant component works by centrally interrupting nerve signals to reduce muscle spasms, a function not shared by typical non-selective anti-inflammatory pain relievers.

Q: Is Dorsilon used for headaches or migraines?

A: The officially approved indication for Dorsilon is limited to the relief of pain and muscle spasms in musculoskeletal conditions. The regulatory label does not list headaches or migraines as an approved indication for use.

Q: What is the risk of dependence or addiction with Dorsilon?

A: Due to the characteristics of the Mephenoxalone component, regulatory guidance requires that healthcare professionals assess patient risk for substance abuse or dependence. Regulatory documents note that chronic, high-dose use of any CNS-active drug can be associated with the development of tolerance and dependence.

Q: Does Dorsilon interfere with laboratory blood tests?

A: Official labels indicate that the Acetaminophen component is known to cause false results in some laboratory tests, particularly with certain methods used to measure blood sugar (glucose). Regulatory labels advise that the drug's use should be noted when laboratory tests are requested.

Q: Is it true that Dorsilon is primarily an anti-inflammatory drug?

A: The drug's official classification is a skeletal muscle relaxant and a miscellaneous analgesic. While its mechanism does involve suppressing pro-inflammatory activity in the cell, its core general purpose remains the combination relief of pain and muscle spasms.

Q: What happens if I accidentally take two doses close together?

A: The prescribing protocol dictates that a minimum time interval between administrations is mandatory. Taking doses too close together increases the risk of exceeding the maximum daily limit and heightens the risk of Acetaminophen-induced liver damage and other dose-related adverse effects.

Q: What is the difference between a side effect and a contraindication for Dorsilon?

A: A side effect (adverse reaction) is an unwanted physical effect that may occur while using the drug, such as dizziness. A contraindication is an absolute medical condition or circumstance, like severe liver disease, that strictly prohibits the drug's use due to a high risk of serious harm.

Q: How is the official mechanism of action described in patient information?

A: Patient-friendly descriptions state the Mephenoxalone component helps to interrupt nerve signals in the spinal cord to reduce muscle spasm. Concurrently, the Acetaminophen component works to increase the body's overall pain threshold.

Q: Does Dorsilon interact with common herbal supplements like St. John's Wort?

A: Regulatory agencies advise caution with many herbal and dietary supplements. The risk of an interaction, particularly with supplements that affect the central nervous system, is that they may increase the sedative effects of Dorsilon. Official guidance emphasizes the importance of disclosing all supplements to the prescribing healthcare professional.

Q: What is the typical timeframe for seeing the full effects of Dorsilon?

A: Research evidence focused on the short-term, acute relief of symptoms, with studies often lasting only a few days. The full expected relief for an acute episode is commonly observed within the first few days of use, which is consistent with the medicine's short-term-only protocol.

How should Dorsilon be stored and disposed of?

How to Store and Dispose of Dorsilon?

The storage and disposal of Dorsilon tablets must follow official regulatory requirements to ensure product stability and safety.

Storage Requirements

Dorsilon must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The product must be kept in its original container, which should be tightly closed and stored in a dry place. It is essential to protect the medicine from moisture, excessive heat, and freezing. To prevent accidental ingestion, Dorsilon must be stored out of the reach and sight of children.

Disposal Instructions

Unused or expired Dorsilon should be disposed of via a drug take-back program if one is available. If a take-back program is not accessible, the medicine can be prepared for disposal in the household trash by mixing it with an undesirable substance, then placing it in a sealed container. Do not flush Dorsilon down the toilet or pour it into the drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dorsilon found in:

A-Z Index: